Regulatory and political changes
Drug development and commercialization depend on changing healthcare rules and approval standards.
- Scope
- Development timelines, market access, and compliance costs
- Materiality
- high
Orexo
Orexo is a Swedish pharmaceutical company focused on developing, manufacturing, and commercializing proprietary drug products and drug-delivery technologies. Its portfolio includes marketed medicines such as Zubsolv, Abstral, Edluar, vorvida, and MODIA, alongside the AmorphOX powder-based delivery platform and related development collaborations.
72
3.70
3.65
| % | |
|---|---|
| Prescription medicines | 55% Branded pharmaceutical products sold through commercial and partner channels. |
| Drug-delivery technology | 20% AmorphOX platform and related formulation capabilities licensed or partnered with others. |
| Digital therapeutics | 5% Software-based products used to support treatment and patient engagement. |
| Development and collaboration revenue | 20% Revenue from partnering, formulation work, and related development services. |
Orexo sells to wholesalers, commercial partners, and other counterparties involved in pharmaceutical distribution and...
- Pharmaceutical wholesalersprimary
Buy finished medicines for downstream distribution to pharmacies and healthcare channels.
- Commercial partnersprimary
License or collaborate on AmorphOX formulations and related product development.
- Patients and prescriberssecondary
Use Orexo-branded therapies such as Zubsolv, Abstral, and Edluar through the healthcare system.
- Digital health usersemerging
Adopt vorvida and MODIA for treatment support and behavior-focused care.
- Research and clinical partnerssecondary
Support clinical trials, formulation work, and product development programs.
Orexo’s revenue is concentrated in the US and Europe, with the 2025 note showing EU & UK as the largest market and the...
- •EU & UK is the largest reported revenue market
- •The US remains an important commercial market for Orexo products
- •Rest of world sales indicate selective international reach
- •Currency exposure is meaningful because revenues and costs are partly USD-based
- •Geography matters because regulation and reimbursement vary by market
Orexo’s strategy centers on innovation in drug formulation and on expanding the AmorphOX platform through partnerships...
01
Expand AmorphOX partnershipsmedium-term
Partnerships can scale the platform across more molecules and indications without relying only on internal commercialization.
02
Advance proprietary product innovationmedium-term
New formulations and products support differentiation and extend the company’s commercial base.
03
Strengthen IP and patent protectionlong-term
Intellectual property helps defend product value and supports long-term partnering economics.
Orexo faces typical pharmaceutical risks around regulation, clinical development, product quality, and supply chain...
Clinical trial execution risk
Protocol deviations, safety incidents, or GCP noncompliance can delay programs and damage credibility.
- Scope
- Pipeline development and regulatory submissions
- Materiality
- high
Supply chain and manufacturing risk
Dependence on suppliers and contract manufacturing can create quality or continuity issues.
- Scope
- Product supply, launch timing, and cost of goods
- Materiality
- high
IT and cyber security risk
Data breaches, malware, phishing, and hardware failures can disrupt operations and expose sensitive information.
- Scope
- Operational continuity and confidential data
- Materiality
- medium
Foreign exchange risk
A meaningful share of revenues and expenses is denominated in USD, creating transaction and translation exposure.
- Scope
- Reported earnings and equity
- Materiality
- medium
Revenue recognition with variable consideration
Net sales and provisions
Inventory valuation and obsolescence
Cost of goods sold and inventory carrying value
Accounts receivable and customer concentration
Credit losses and working capital
Foreign currency accounting
Financial items and equity
Borrowings and lease accounting
Net financial items and liabilities
: 11/08/2026